Monitoring of plasma disappearance rate of indocyanine green in a patient with necrotizing fasciitis and septic shock;Überwachung der plasmaeliminationsrate von indocyaningrün bei einem patienten mit nekrotisierender fasziitis und septischem schock

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 48, 2004, Pages 2590-2593

  Kortgen, A ^a   Lindemann, W ^a   Bauer, M ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; HYDROCORTISONE; INDOCYANINE GREEN; INSULIN; ANTIINFECTIVE AGENT; COLORING AGENT;

ABDOMEN; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DETERIORATION; DIABETES MELLITUS; ECHOCARDIOGRAPHY; FEVER; HUMAN; HYPERTENSION; INSULIN TREATMENT; MALE; NECROTIZING FASCIITIS; SEPTIC SHOCK; SKULL; THORAX; BLOOD; CASE REPORT; DRUG COMBINATION; DRUG MONITORING; METABOLIC CLEARANCE RATE; METHODOLOGY; MIDDLE AGED; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

ANTI-BACTERIAL AGENTS; COLORING AGENTS; DRUG MONITORING; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; HUMANS; HYDROCORTISONE; INDOCYANINE GREEN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; SHOCK, SEPTIC;

EID: 9944243246     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-836080     Document Type: Article

References (12)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. The epidemiology of sepsis in the United States: analysis of incidence, outcome and associated costs of Care. Crit Care Med 2001; 29: 1303-1310
2. Annane D, Sebille V, Charpentier C et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-871
3. Bauer M, Paxian M, Kortgen A. Akutes Leberversagen - aktuelle Aspekte zur Diagnostik und Therapie. Anaesthesist 2004; 53: 511-530
4. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
5. Dellinger RP, Carlet JM, Masur H et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004; 30: 536-555
6. Hawker F. Liver dysfunction in critical illness. Anaesth Intensive Care 1991; 19: 165-181
7. Kimura S, Yoshioka T, Shibuya M, Sakano T, Tanaka R, Matsuyama S. Indocyanine green elimination rate detects hepatocellular dysfunction early in septic shock and correlates with survival. Crit Care Med 2001; 29: 1159-1163
8. Rensing H, Bauer I, Zhang JX et al. Endothelin-1 and heme oxygenase-1 as modulators of sinusoidal tone in the stress-exposed rat liver. Hepatology 2002; 36: 1453-1465
9. Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377
10. Sakka SG, Reinhart K, Meier-Hellmann A. Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients. Chest 2002; 122: 1715-1720
11. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Crit Care Med 1999; 27: 639-660
12. Van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359-1367